Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
16.75
-0.33 (-1.93%)
At close: Oct 21, 2025, 4:00 PM EDT
16.75
0.00 (0.00%)
After-hours: Oct 21, 2025, 4:10 PM EDT
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$2,161,707
Market Cap
2.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 191 | 50 | 35.46% |
Dec 31, 2023 | 141 | 22 | 18.49% |
Dec 31, 2022 | 119 | 26 | 27.96% |
Dec 31, 2021 | 93 | 46 | 97.87% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
DYN News
- 13 days ago - Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 - Seeking Alpha
- 14 days ago - Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 19 days ago - Dyne Therapeutics Appoints Brian Posner to its Board of Directors - GlobeNewsWire
- 22 days ago - Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 7 weeks ago - Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 3 months ago - These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga